PEPTIDE THERAPY CLINIC BUSINESS PLAN

I. Executive Summary

Company Description

Aurelon Clinic—named to evoke clinical rigor and longevity—launches in 2026 in a major U.S. metropolitan area. We operate in the medical-wellness sector, delivering physician-led, fee-for-service advanced peptide therapies and personalized longevity protocols. Our core offerings are data-driven diagnostic assessments, individualized peptide regimens, metabolic and cognitive optimization plans, and ongoing clinical monitoring using state-of-the-art lab and imaging technology. One line: we turn clinical data into tailored, high-touch performance and longevity plans.

Day-to-day we run comprehensive intake testing, physician consultations, on-site administrations, telehealth follow-ups, and longitudinal biomarker tracking. We target affluent adults seeking health optimization and preventive longevity care. Short-term goals: open in 2026, prove clinical outcomes, and reach sustainable margins within 18 months. Long-term goals: expand to multiple metropolitan clinics, standardize protocols, and offer scalable telehealth and diagnostics by 2030. One line: we compete on medical quality, measurable outcomes, and concierge service.

Problem

Older adults in major U.S. metropolitan areas experience measurable declines in energy, recovery, and cognitive function and lack access to coordinated, proactive medical programs that prevent decline rather than treat it reactively. These patients need personalized, data-driven biological optimization to restore performance.

Current care is fragmented: conventional medicine rarely pairs comprehensive clinical biomarker analysis with medically supervised peptide therapies, leaving a gap where slower recovery, unmanaged functional decline, and no centralized, actionable treatment plans are the norm. A high-end, physician-led clinic that combines advanced diagnostics with targeted peptide protocols is required to address this unmet need.

Solution

Many adults face declining vitality, energy, and recovery that conventional care does not proactively treat. Our offering is a physician-led, data-driven clinical model delivering personalized peptide therapies built on advanced diagnostic testing, continuous biomarker monitoring, and medically supervised dose adjustments to target cognitive clarity, physical recovery, and long-term healthspan.

One clear line: we provide medically supervised, precision peptide protocols that combine diagnostic rigor with performance-focused care for clients who require professional, data-oriented clinical settings.

Mission Statement

Our mission is to empower individuals to achieve peak biological potential through physician-led, data-driven peptide therapies that deliver measurable improvements in vitality, recovery, and long-term healthspan. We provide personalized, medically supervised care grounded in scientific rigor and premium clinical standards. We commit to proactive, evidence-based treatments that produce life-changing results for clients at every stage of life.

Key Success Factors

Core capabilities and market advantages that will drive clinic performance and investor returns.

• Physician-led clinical team ensuring medical-grade safety and protocol efficacy.
• Data-driven personalization using comprehensive biomarker analysis for tailored treatments.
• Affluent metropolitan location positioning the clinic to attract high-net-worth clients.
• FDA-compliant compounding partnerships guaranteeing high-quality peptide sourcing.
• Proven financial returns with a 15.2% IRR and a 13-month payback period.

Financial Summary

Financial highlights show a high-margin clinic reaching early breakeven and rapid EBITDA growth over five years.

Financial requirements: total launch capital expenditures of $410,500 and a minimum cash buffer of $746,000; returns: breakeven in Jan-26 (month 1), payback in 13 months, and an IRR of 15.2%.

The forecast shows strong profitability and a clear path to significant enterprise value by Year 5.

Funding Requirements

We require $746,000 to launch — covering $410,500 in CapEx and $345,500 in working capital — to reach Month 1 breakeven and deliver 2026 revenue of $1,469,000 with $500,000 EBITDA, scaling to $9,272,000 revenue and $7,668,000 EBITDA by Year 5 and achieving a 19.53% return on equity.